Genetics and neuropathology of huntington's disease

International Review of Neurobiology

Volumn 98, Issue , 2011, Pages 325-372

  Reiner, Anton ^a   Dragatsis, Ioannis ^a   Dietrich, Paula ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Akinesia; Basal ganglia; CAG repeat; Chorea; Neurodegeneration; Striatum

Indexed keywords

HUNTINGTIN; MESSENGER RNA;

AMYGDALOID NUCLEUS; BOOK; BRAIN DEVELOPMENT; CAG REPEAT; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE TRANSMISSION; GAIN OF FUNCTION MUTATION; GENE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC SUSCEPTIBILITY; GENOMIC INSTABILITY; GLOBUS PALLIDUS; HUMAN; HUNTINGTIN ASSOCIATED PROTEIN 1 GENE; HUNTINGTIN GENE; HUNTINGTON CHOREA; HYPOTHALAMUS; INTERNEURON; MUTATIONAL ANALYSIS; MUTATOR GENE; NERVE PROJECTION; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; ONSET AGE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PURKINJE CELL; SUBSTANTIA NIGRA; THALAMUS VENTRAL NUCLEUS;

EID: 80052533413     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381328-2.00014-6     Document Type: Chapter

References (305)

1. Albin R.L., Qin Y., Young A.B., Penney J.B., Chesselet M.F. Preproenkephalin messenger RNA-containing neurons in striatum of patients with symptomatic and presymptomatic Huntington's disease: an in situ hybridization study. Ann. Neurol. 1991, 30:542-549.
2. Albin R.L., Reiner A., Anderson K.D., Dure L.S.IV, Handelin B., Balfour R., Whetsell W.O., Penney J.B., Young A.B. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann. Neurol. 1992, 31:425-430.
3. Albin R.L., Reiner A., Anderson K.D., Penney J.B., Young A.B. Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional anatomy of chorea and rigidity-akinesia. Ann. Neurol. 1990 a, 27:357-365.
4. Albin R.L., Tagle D.A. Genetics and molecular biology of Huntington's disease. Trends Neurosci. 1995, 18:11-14.
5. Albin R.L., Young A.B., Penney J.B., Handelin B., Balfour R., Anderson K.D., Markel D.S., Tourtellotte W.W., Reiner A. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. N. Engl. J. Med. 1990 b, 332. 1923-1298.
6. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989, 12:366-375.
7. Allen K.L., Waldvogel H.J., Glass M., Faull R.L. Cannabinoid (CB1), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease. J Chem Neuroanat 2009, 37:266-281.
8. Alonso M.E., Yescas P., Rasmussen A., Ochoa A., Macías R., Ruiz I., Suástegui R. Homozygosity in Huntington's disease: new ethical dilemma caused by molecular diagnosis. Clin Gen 2002, 61:437-442.
9. Andresen J.M., Javiar G., Djousse L., Roberts S., Brocklebank D., Cherny S.S., The HD-MAPS Collaborative Research Group, Cardon L.R., Gusella J.F., MacDonald M.F., Myers R.H., Houseman D.E., Wexler N.S. The relationship between CAG repeat length and age of onset differs for Huntington's disease patients with juvenile onset or adult onset. Ann. Hum. Gen. 2006, 71:295-301. The US-Venezuela-Collaborative Research Group.
10. Andrew S.E., Goldberg Y.P., Kremer B., Telenius H., Theilmann J., Adam S., Starr E., Squitieri F., Lin B., Kalchman M.A., Graham R.K., Hayden M.R. The relationship between trinucleotide (CAG) repeat length and the clinical features of Huntington's disease. Nat. Gen. 1993, 4:398-403.
11. Andrich J., Arning L., Wieczorek S., Kraus P.H., Gold R., Saft C. Huntington's disease as caused by 34 repeats. Movement Dis. 2008, 23:879-881.
12. Antonini A., Leenders K.L., Spiegel R., Meier D., Vontobel P., Weigell-Weber M., Sanchez-Pernaute R., de Yebenez J.G., Boesinger P., Weindl A., Maguire R.P. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 1996, 11:2085-2095.
13. Aquilonius A.M., Eckernas S.A., Sundwall A. Regional distribution of choline acetyltransferase in the human brain: changes in Huntington's chorea. J. Neurol. Neurosurg. Psychiatry 1975, 38:669-677.
14. Arsenault M.Y., Parent A., Seguela P., Descarries L. Distribution and morphological characteristics of dopamine-immunoreactive neurons in the midbrain of the Squirrel monkey (Saimiri sciureus). J. Comp. Neurol. 1988, 267:489-506.
15. Atwal R.S., Xia J., Pinchev D., Taylor J., Epand R.M., Truant R. Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum. Mol. Evol. 2007, 16:2600-2615.
16. Augood S.J., Faull R.L.M., Emson P.C. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann. Neurol. 1997, 42:215-221.
17. Augood S.J., Faull R.L.M., Love D.R., Emson P.C. Reduction in enkephalin and substance P mRNA in the striatum of early grade Huntington's disease:a detailed cellular in situ hybridization study. Neuroscience 1996, 72:1023-1036.
18. Aylward E.H., Brandt J., Codori A.M., Mangus R.S., Barta P.E., Harris G.J. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology 1994, 44:823-828.
19. Aylward E.H., Codori A.M., Barta P.E., Pearlson G.D., Harris G.J., Brandt J. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch. Neurol. 1996, 53:1293-1296.
20. Barnes G.T., Duyao M.P., Ambrose C.M., McNeil S., Persichetti F., Srinidhi J., Gusella J.F., MacDonald M.E. Mouse Huntington's disease gene homolog (Hdh). Somat. Cell Mol. Gen. 1994, 20:87-97.
21. Bates G.P., Mangiarini L., Mahal A., Davies S.W. Transgenic models of Huntington's disease. Hum. Mol. Gen. 1997, 6:1633-1637.
22. Baxendale S., Abdulla S., Elgar G., Buck D., Berks M., Micklem G., Durbin R., Bates G., Brenner S., Beck S. Comparative sequence analysis of the human and pufferfish Huntington's disease genes. Nature Gen. 1995, 10:67-76.
23. Beal M.F., Ferrante R.J., Swartz K.J., Kowall N.W. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci. 1991, 11:1649-1659.
24. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J., Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986, 321:168-171.
25. Beal M.F., Ellison D.W., Mazurek M.F., Swartz K.J., Malloy J.R., Bird E.D., Martin J.B. A detailed examination of substance P in pathologically graded cases of Huntington's disease. J. Neurol. Sci. 1988, 84:51-61.
26. Beckstead R.M., Cruz C.J. Striatal axons to the globus pallidus, entopeduncular nucleus and substantia nigra come mainly from separate cell populations in cat. Neuroscience 1986, 19:147-158.
27. Behrens P.F., Franz P., Woodman B., Lindenberg K.S., Landwehrmeyer G.B. Impaired glutamate transport and glutamate-glutamine cycling:downstream effects of the Huntington mutation. Brain 2002, 125:1908-1922.
28. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteosome system by protein aggregation. Science 2001, 292:1552-1555.
29. Bennett B.D., Bolam J.P. Characterization of calretinin-immunoreactive structures in the striatum of the rat. Brain Res. 1993, 609:137-148.
30. Bennett B.D., Callaway J.C., Wilson C.J. Intrinsic membrane properties underlying spontaneous tonic firing in neostriatal cholinergic interneurons. J. Neurosci. 2000, 20:8493-8503.
31. Berke J.D. Uncoordinated firing rate changes of striatal fast-spiking interneurons during behavioral task performance. J. Neurosci. 2008, 40:10075-10080.
32. Bhide P.G., Day M., Sapp E., Schwarz C., Sheth A., Kim J., Young A.B., Penney J., Golden J., Aronin N., DiFiglia M. Expression of normal and mutant huntingtin in the developing brain. J. Neurosci. 1996, 17:5523-5535.
33. Bohnen N.I., Koeppe R.A., Meyer P., Ficaro E., Wernette K., Kilbourn M.R., Kuhl D.E., Frey K.A., Albin R.L. Decreased striatal monoaminergic terminals in Huntington disease. Neurology 2000, 54:1753-1759.
34. Bossy-Wetzel E., Petrilli A., Knott A.B. Mutant huntingtin and mitochondrial dysfunction. Trends Neurosci 2008, 31:609-616.
35. Braak H., Braak E. Allocortical involvement in Huntington's disease. Neuropathol Appl Neurobiol 1992, 18:539-547.
36. Brinkman R.R., Mezei M.M., Theilmann J., Almqvist E., Hayden M.R. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum. Gen. 1997, 60:1202-1210.
37. Bruyn G.W., Went L.N. Huntington's chorea. Handbook of clinical neurology 1986, 5:267-313. Elsevier, Amsterdam.
38. Buck S.H., Burks T.F., Brown M.R., Yamamura H.I. Reduction in basal ganglia and substantia nigra substance P level in Huntington's disease. Brain Res 1981, 209:464-469.
39. Byers R.K., Gilles F.H., Fung C. Huntington's disease in children. Neuropathological study of four cases. Neurology 1983, 23:561-569.
40. Calabresi P., Centonze D., Pisani A., Sancesario G., Gubellini P., Marfia G.A., Bernardi G. Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability:implications for ischemia and Huntington's disease. Ann. Neurol. 1998, 43:586-597.
41. Canals J.M., Pineda J.R., Torres-Peraza J.F., Bosch M., Martín-Ibañez R., Muñoz M.T., Mengod G., Ernfors P., Alberch J. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J. Neurosci. 2004, 24:7727-7739.
42. Cattaneo E., Zuccato C., Tartari M. Normal Huntingtin function: An alternative approach to Huntington's disease. Nat Rev Neurosci 2005, 6:919-930.
43. Cattaneo E., Rigamonti D., Goffredo D., Zuccato C., Squitieri F., Sipione S. Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci 2001, 24:182-188.
44. Cepeda C., Wu N., Andre V.M., Cummings D.M., Levine M.S. The corticostriatal pathway in Huntington's disease. Prog Neurobiol 2007, 81:253-271.
45. Cha J.H.J., Kosinski C.M., Kerner J.A., Alsdorf S.A., Mangiarini L., Davies S.W., Penney J.B., Bates G.P., Young A.B. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. J. Neurosci. 1998, 19:1189-1202.
46. Chai Y., Koppenhafer S.L., Shoesmith S.J., Perez M.K., Paulson H.L. Evidence for proteosome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum. Mol. Gen. 1999, 8:673-682.
47. Chen Q., Veenman C.L., Reiner A. Cellular expression of ionotropic glutamate receptor subunits on specific striatal neuron types and its implication for striatal vulnerability in glutamate receptor-mediated excitotoxicity. Neuroscience 1996, 73:715-731.
48. Chen Q., Veenman L., Knopp K., Yan Z., Medina L., Song W.J., Surmeier D.J., Reiner A. Evidence for the preferential localization of glutamate receptor-1 subunits of AMPA receptors to the dendritic spines of medium spiny neurons in rat striatum. Neuroscience 1998, 83:749-761.
49. Chong S.S., Almqvist E., Telenius H., LaTray L., Nichol K., Bourdelat-Parks B., Goldberg Y.P., Haddad B.R., Richards F., Sillence D., Greenberg C.R., Ives E., Van den Engh G., Hughes M.R., Hayden M.R. Contribution of DNA sequence and CAG size to mutation frequencies of intermediate alleles for Huntington disease: evidence from single sperm analyses. Hum. Mol. Gen. 1997, 6:301-309.
50. Cicchetti F., Parent A. Striatal interneurons in Huntington's disease: selective increase in the density of calretinin-immunoreactive medium-sized neurons. Mov Disord 1996, 11:619-626.
51. Cicchetti F., Prensa L., Wu Y., Parent A. Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington's disease. Brain Res. Rev. 2000, 34:80-101.
52. Coles R., Caswell R., Rubinsztein D.C. Functional analysis of the Huntington's disease (HD) gene promoter. Hum. Mol. Gen. 1998, 7:791-800.
53. Cowan C.M., Raymond L.A. Selective neuronal degeneration in Huntington's disease. Curr Top Dev Biol 2006, 75:25-71.
54. Crossman A.R. Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders. Neuroscience 1987, 21:1-40.
55. Cudkowicz M., Kowall N.S. Degeneration of pyramidal projection neurons in Huntington's disease cortex. Ann. Neurol. 1990, 27:200-204.
56. Culjkovic B., Stojkovic O., Vojvodic N., Svetel M., Rakic L., Romac S., Kostic V. Correlation between triplet repeat expansion and computed tomography measures of caudate nuclei atrophy in Huntington's disease. J Neurol 1999, 246:1090-1093.
57. Curtis M.A., Penney E.B., Pearson A.G., van Roon-Mom W.M., Butterworth N.J., Dragunow M., Connor B., Faull R.L. Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain. Proc. Natl. Acad. Sci. USA 2003, 100:9023-9027.
58. Curtis M.A., Waldvogel H.J., Synek B., Faull R.L. A histochemical and immunohistochemical analysis of the subependymal layer in the normal and Huntington's disease brain. J Chem Neuroanat 2005 a, 30:55-66.
59. Curtis M.A., Penney E.B., Pearson J., Dragunow M., Connor B., Faull R.L. The distribution of progenitor cells in the subependymal layer of the lateral ventricle in the normal and Huntington's disease human brain. Neuroscience 2005 b, 132:777-788.
60. Curtis M.A., Eriksson P.S., Faull R.L. Progenitor cells and adult neurogenesis in neurodegenerative diseases and injuries of the basal ganglia. Clin Exp Pharmacol Physiol 2007, 34:528-532.
61. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997, 90:537-548.
62. Dawbarn D., DeQuidt M.E., Emson P.C. Survival of basal ganglia neuropeptide Y-somatostatin neurons in Huntington's disease. Brain Res 1985, 340:251-260.
63. De La Monte S.M., Vonsattel J.P., Richardson E.P. Morphometric demonstrations of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J. Neuropathol. Exp. Neurol. 1988, 44:516-525.
64. Deng Y.P., Penney J.B., Young A.B., Albin R.L., Anderson K.D., Reiner A. Differential loss of striatal projection neurons in Huntington's disease: A quantitative immunohistochemical study. J Chem Neur 2004, 27:143-164.
65. De Rooij K.E., De Koning Gans P.A., Roos R.A., Van Ommen G.J., Den Dunnen J.T. Somatic expansion of the (CAG)n repeat in Huntington disease brains. Hum. Gen. 1995, 95:270-274.
66. DiFiglia M., Sapp E., Chase K., Schwarts C., Meloni A., Young C., Martin E., Vonsattel J.P., Carraway R., Reeves S.A., Boyce F.M., Aronin N. Huntingtin is a cytoplasmatic protein associated with vesicles in human and rat brain neurons. Neuron 1995, 14:1075-1081.
67. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin J.P. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
68. DiFiglia M. Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci 1990, 13:286-289.
69. DiLeone R.J., Georgescu D., Nestler E.J. Lateral hypothalamic neuropeptides in reward and drug addiction. Life Sci. 2003, 73:759-768.
70. Djoussé L., Knowlton B., Hayden M., Almqvist E.W., Brinkman R., Ross C., Margolis R., Rosenblatt A., Dürr A., Dode C., Morrison P.J., Novelletto A., Frontali M., Trent R.J., McCusker E., Gómez-Tortosa E., Mayo D., Jones R., Zanko A., Nance M., Abramson R., Suchowersky O., Paulsen J., Harrison M., Yang Q., Cupples L.A., Gusella J.F., MacDonald M.E., Myers R.H. Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. Am J Med Gen A. 2003, 119A::279-282.
71. Dom R., Malfroid M., Baro F. Neuropathology of Huntington's chorea. Studies of the ventrobasal complex of the thalamus. Neurology 1976, 26:64-68.
72. Dorsman J.C., Smoor M.A., Maat-Schieman M.L.C., Bout M., Siesling S., van Duinen S.G., Verschuuren J.J., den Dunnen J.T., Roos R.A., van Ommen G.J. Analysis of the subcellular localization of huntingtin with a set of rabbit polyclonal antibodies in cultured mammalian cells of neuronal origin: comparison with distribution of huntingtin in Huntington's disease autopsy brain. Phil Trans R Soc Lond 1999, 354:1061-1067.
73. Douaud G., Behrens T.E., Poupon C., Cointepas Y., Jbabdi S., Gaura V., Golestani N., Krystkowiak P., Verny C., Damier P., Bachoud-Lévi A.C., Hantraye P., Remy P. In vivo evidence for the selective subcortical degeneration in Huntington's disease. NeuroImage 2009, 46:958-966.
74. Douaud G., Gaura V., Riveiro M.J., Lethimonnier F., Maroy R., Vemy C., Krystkowiak P., Damier P., Bachoud-Levi A.C., Hantraye P., Remy P. Distribution of grey matter atrophy in Huntington's disease patients: a combined ROI-based and voxel-based morphometric study. Neuroimage 2006, 32:1562-1575.
75. Dürr A., Hahn-Barma V., Brice A., Pêcheux C., Dodé C., Feingold J. Homozygosity in Huntington's disease. J Med Gen 1999, 36:172-173.
76. Duyao M., Ambrose C., Myers R., Novelletto A., Persichetti F., Frontali M., Folstein S., Ross C., Franz M., Abbott M., Gray J., Conneally P., Young A., Penney J., Hollingsworth Z., Shoulson I., Lazzarini A., Falek A., Koroshetz W., Sax D., Bird E., Vonsattel J., Bonilla E., Alvir J., Bickham Conde J., Cha J.H., Dure L., Gomez F., Ramos M., Sanchez-Ramos J., Snodgrass S., de Young M., Wexler N., Moscowitz C., Penchaszadeh G., MacFarlane H., Anderson M., Jenkins B., Srinidhi J., Barnes G., Gusella J., MacDonald M. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat. Gen. 1993, 4:387-392.
77. Ellison D.W., Beal M.F., Mazurek M.F., Malloy J.R., Bird E.D., Martin J.B. Amino acid neurotransmitter abnormalities in Huntington's disease and the quinolinic acid animal model of Huntington's disease. Brain 1987, 110:1657-1673.
78. Emson P.C., Arregui A., Clement-Jones V., Sandberg B.E.B., Rossor M. Regional distribution of methionine-enkephalin and substance P-like immunoreactivity in normal human brain and in Huntington's disease. Brain Res 1980, 199:147-160.
79. Feger J., Crossman A.R. Identification of different subpopulations of neostriatal neurons projecting to globus pallidus or substantia nigra in the monkey: a retrograde fluorescence double-labeling study. Neurosci. Lett. 1984, 49:7-12.
80. Ferrante R.J., Beal M.F., Kowall N.W., Richardson E.P., Martin J.B. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res 1987 b, 411:162-166.
81. Ferrante R.J., Kowall N.W., Beal M.F., Martin J.B., Bird E.D., Richardson E.P. Morphological and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. J. Neuropathol. Exp. Neurol. 1987 a, 46:12-27.
82. Ferrante R.J., Kowall N.W., Beal M.F., Richardson E.P., Bird E.D., Martin J.B. Selective sparing of a class of striatal neurons in Huntington's disease. Science 1985, 230:561-563.
83. Ferrante R.J., Kowall N.W., Richardson E.P., Bird E.D., Martin J.B. Topography of enkephalin, substance P, and acetylcholinesterase staining in Huntington's disease striatum. Neurosci. Lett. 1986, 71:283-288.
84. Ferrer I., Kulisevsky J., Gonzalez G., Escartin A., Chivite A., Casas R. Parvalbumin-immunoreactive neurons in the cerebral cortex and striatum in Huntington's disease. Neurodegeneration 1994, 3:169-173.
85. Figueredo-Cardenas G., Morello M., Sancesario G., Bernardi G., Reiner A. Colocalization of somatostatin, neuropeptide Y, neuronal nitric oxide synthase and NADPH-diaphorase in striatal interneurons in rats. Brain Res 1996 a, 735:317-324.
86. Figueredo-Cardenas G., Medina L., Reiner A. Calretinin is localized to a unique population of striatal interneurons in rats. Brain Res. 1996 b, 709:145-150.
87. Figueredo-Cardenas G., Harris C., Anderson K.D., Reiner A. Relative resistance of striatal neurons containing calbindin or parvalbumin to quinolinic acid-mediated excitotoxicity compared to other striatal neuron types. Exp. Neurol. 1998, 149:356-372.
88. Fink J.S., Weaver D.R., Rivkees S.A., Peterfreund R.A., Pollack A.E., Adler E.M., Reppert S.M. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Mol. Brain Res. 1992, 14:186-195.
89. Flaherty A.W., Graybiel A.M. Output architecture of the primate putamen. J. Neurosci. 1993, 13:3222-3237.
90. Fossale E., Wheeler V.C., Vrbanac V., Lebel L.A., Teed A., Mysore J.S., Gusella J.F., MacDonald M.E., Persichetti F. Identification of a presymptomatic molecular phenotype in Hdh CAG knock-in mice. Hum. Mol. Gen. 2002, 11:2233-2241.
91. Fusco F.R., Chen Q., Lamoreaux W.J., Figueredo-Cardenas G., Jiao Y., Coffman J., Surmeier D.J., Honig M.G., Carlock L.R., Reiner A. Cellular localization of huntingtin in striatal and cortical neurons in rats: Lack of correlation with neuronal vulnerability in Huntington's disease. J. Neurosci. 1999, 19:1189-1202.
92. Gabery S., Murphy K., Schultz K., Loy C.T., McCusker E., Kirik D., Halliday G., Petersén A. Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. Acta Neuropathol 2010, 120:777-788.
93. Gage G.J., Stoetzner C.R., Wiltschko A.B., Berke J.D. Selective activation of striatal fast-spiking interneurons during choice execution. Neuron 2010, 67:466-479.
94. Gale G.S., Bird E.D., Spokes E.G., Iversen L.L., Jessell T. Human brain substance P: distribution in controls and Huntington's chorea. J Neurochem 1977, 30:633-634.
95. Gayán J., Brocklebank D., Andresen J.M., Alkorta-Aranburu G., Zameel Cader M., Roberts S.A., Cherny S.S., Wexler N.S., Cardon L.R., Housman D.E. Genomewide linkage scan reveals novel loci modifying age of onset of Huntington's disease in the Venezuelan HD kindreds. Gen Epidemiol 2008, 32:445-453. US-Venezuela Collaborative Research Group.
96. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci 1992, 15:133-139.
97. Gervais F.G., Singaraja R., Xanthoudakis S., Gutekunst C.A., Leavitt B.R., Metzler M., Hackam A.S., Tam J., Vaillancourt J.P., Houtzager V., Rasper D.M., Roy S., Hayden M.R., Nicholson D.W. Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nat Cell Biol 2002, 4:95-105.
98. Gimenez-Amaya J.M., Graybiel A.M. Modular organization of projection neurons in the matrix compartment of the primate striatum. J. Neurosci. 1991, 11:779-791.
99. Glass M., Dragunow M., Faull R.L.M. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997, 77:299-318.
100. Glass M., Dragunow M., Faull R.L.M. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000, 97:505-519.
101. Gómez-Tortosa E., MacDonald M.E., Friend J.C., Taylor S.A., Weiler L.J., Cupples L.A., Srinidhi J., Gusella J.F., Bird E.D., Vonsattel J.P., Myers R.H. Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann. Neurol. 2001, 49:29-34.
102. Goto S., Hirano A., Rojas-Corona R.R. Immunohistochemical visualization of afferent nerve terminals in human globus pallidus and its alteration in neostriatal neurodegenerative disorders. Acta Neuropathol 1989 a, 78:543-550.
103. Goto S., Hirano A., Rojas-Corona R.R. An immunohistochemical investigation of the human neostriatum in Huntington's disease. Annals Neurol 1989 b, 25:298-304.
104. Grafton S.T., Mazziotta J.C., Pahl J.J., St George-Hyslop P., Haines J.L., Gusella J., Hoffman J.M., Baxter L.R., Phelps M.E. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch Neurol 1992, 49:1161-1167.
105. Graham R.K., Slow E.J., Deng Y., Bissada N., Lu G., Pearson J., Shehadeh J., Leavitt B.R., Raymond L.A., Hayden M.R. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. Neurobiol Dis. 2006, 21:444-455.
106. Gusella J.F., MacDonald M.E. Huntington's disease: the case for genetic modifiers. Genome Med 2009, 1:80.1-80.6.
107. Gusella J.F., Wexler N.S., Conneally P.M., Naylor S.L., Anderson M.A., Tanzi R.E., Watkins P.C., Ottina K., Wallace M.R., Sakaguchi A.Y., Young A.B., Shoulson I., Bonilla E., Martin J.B. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 1983, 306:234-238.
108. Gusella J.F., MacDonald M.E., Ambrose C.M., Duyao M.P. Molecular Genetics of Huntington's Disease. Arch Neurol. 1994, 50:1157-1163.
109. Gutekunst C.A., Levey A.I., Heilman C.J., Whaley W.L., Yi H., Nash N.R., Rees H.D., Madden J.J., Hersh S.M. Identification and localization on huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proc. Natl. Acad. Sci. USA 1995, 92:8710-8714.
110. Gutekunst C.A., Li S.H., Yi H., Mulroy J.S., Kuemmerle S., Jones R., Rye D., Ferrante R.J., Hersch S.M., Li X.J. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 1999, 19:2522-2534.
111. Hackham A.S., Yassa A.S., Singaraja R., Metzler M., Gutekunst C.A., Gan L., Warby S., Wellington C.L., Vaillancourt J., Chen N., Gervais F.G., Raymond L., Nicholson D.W., Hayden M.R. Huntingtin interacting protein 1 induces apoptosis via novel caspase-dependent death effector domain. J Biol Chem 2000, 275:41299-41308.
112. Hackham A.S., Singaraja R., Wellington C.L., Metzler M., Zhang Z., Kalchman M., Hayden M.R. The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol 1998 b, 141:1097-1105.
113. Hackham A.S., Wellington C.L., Hayden M.R. The fatal attraction of polyglutamine-containing proteins. Clin Gen 1998 a, 53:233-242.
114. Halliday G.M., McRitchie D.A., Macdonald V., Double K.L., Trent R.J., McCusker E. Regional specificity of brain atrophy in Huntington's disease. Exp. Neurol. 1998, 154:663-672.
115. Harjes P., Wanker E.E. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci 2003, 28:225-233.
116. Harrington K.M., Kowall N.W. Parvalbumin immunoreactive neurons resist degeneration in Huntington's disease striatum. J. Neuropathol. Exp. Neurol. 1991, 50:309.
117. Hassel B., Tessler S., Faull R.L., Emson P.C. Glutamate uptake is reduced in prefrontal cortex in Huntington's disease. Neurochem Res 2008, 33:232-237.
118. Hawker K., Lang A.E. Hypoxic-ischemic damage of the basal ganglia: case reports and a review of the literature. Mov Disord 1990, 5:219-224.
119. Hedreen J.C., Folstein S.E. Early loss of neostriatal striosome neurons in Huntington's disease. J. Neuropathol. Exp. Neurol. 1995, 54:105-120.
120. Hedreen J.C., Peyser C.E., Folstein S.E., Ross C.A. Neuronal loss in layers V and VI of cerebral cortex in Huntingon's disease. Neurosci. Lett. 1991, 133:257-261.
121. Heinsen H., Strik M., Bauer M., Luther K., Ulmar G., Gangnus D., Jungkunz G., Eisenmenger W., Götz M. Cortical and striatal neurone number in Huntington's disease. Acta Neuropatho 1994, 88:320-333.
122. Heinsen H., Rüb U., Gangnus D., Jungkunz G., Bauer M., Ulmar G., Bethke B., Schüler M., Böcker F., Eisenmenger W., Götz M., Strik M. Nerve cell loss in the thalamic centromedian-parafascicular complex in patients with Huntington's disease. Acta Neuropathol 1996, 91:161-168.
123. Heinsen H., Rüb U., Bauer M., Ulmar G., Bethke B., Schüler M., Böcker F., Eisenmenger W., Götz M., Korr H., Schmitz C. Nerve cell loss in the thalamic mediodorsal nucleus in Huntington's disease. Acta Neuropathol 1999, 97:613-622.
124. Herkenham M., Lynn A.B., de Costa B.R., Richfield E.K. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. 1991, 547:267-274.
125. Hikosaka O. Role of basal ganglia in saccades. Rev Neurol (Paris) 1989, 145:580-586.
126. Hodges A., Strand A.D., Aragaki A.K., Kuhn A., Sengstag T., Hughes G., Elliston L.A., Hartog C., Goldstein D.R., Thu D., Hollingsworth Z.R., Collin F., Synek B., Holmans P.A., Young A.B., Wexler N.S., Delorenzi M., Kooperberg C., Augood S.J., Faull R.L., Olson J.M., Jones L., Luthi-Carter R. Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Gen. 2006, 15:965-977.
127. Hökfelt T., Martensson R., Björklund A., Kleinau S., Goldstein M. Distributional maps of tyrosine hydroxylase-immunoreactive neurons in the rat brain. Handbook of Chemical Neuroanatomy, vol. 2. Classical Transmitter in the CNS. Part I 1984, 277-379. Elsevier, Amsterdam, The Netherlands. A. Björklund, T. Hökfelt (Eds.).
128. Huang Q., Zhou D., Sapp E., Aizawa H., Ge P., Bird E.D., Vonsattel J.P., DiFiglia M. Quinolinic acid induced increases in calbindin D28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease. Neuroscience 1995, 65:397-407.
129. A novel gene containing a trinucleotide repeat that is expanded and unstable on the HD chromosome. Cell 1993, 72:971-983. Huntington's Disease Collaborative Research Group.
130. Jech R., Klempír J., Vymazal J., Zidovská J., Klempírová O., Růzicka E., Roth J. Variation of selective gray and white matter atrophy in Huntington's disease. Movement Dis 2007, 22:1783-1789.
131. Joshi P.R., Wu N.P., Andre V.M., Cummings D.M., Cepeda C., Joyce J.A., Carroll J.B., Leavitt B.R., Hayden M.R., Levine M.S., Bamford N.S. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J. Neurosci. 2009, 29:2414-2427.
132. Kanazawa I., Bird E., O'Connell R., Powell D. Evidence for a decrease in substance P content of substantia nigra in Huntington's chorea. Brain Res. 1977, 120:387-392.
133. Kanazawa I., Bird E.D., Gale J.S., Iversen L.L., Jessell T.M., Muramoto O., Spokes E.G., Sutoo D. Substance P: decrease in substantia nigra and globus pallidus in Huntington's disease. Advances in Neurology 1979, 23:495-504.
134. Karlovich C.A., John R.M., Ramirez L., Stainier D.Y., Myers R.M. Characterization of the Huntington's disease (HD) gene homologue in the zebrafish Danio rerio. Gene 1998, 217:117-125.
135. Kassubek J., Juengling F.D., Ecker D., Landwehrmeyer G.B. Thalamic atrophy in Huntington's disease co-varies with cognitive performance: a morphometric MRI analysis. Cerebral Cortex 2004 a, 15:846-853.
136. Kassubek J., Juengling F.D., Kioschies T., Henkel K., Karitzky J., Kramer B., Ecker D., Andrich J., Saft C., Kraus P., Aschoff A.J., Ludolph A.C., Landwehrmeyer G.B. Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J Neurol Neurosurg Psychiatry 2004 b, 75:213-220.
137. Kassubek J., Bernhard Landwehrmeyer G., Ecker D., Juengling F.D., Muche R., Schuller S., Weindl A., Peinemann A. Global cerebral atrophy in early stages of Huntington's disease: quantitative MRI study. Neuroreport 2004 c, 15:363-365.
138. Kawaguchi Y., Wilson C.J., Augood S.J., Emson P.C. Striatal interneurons: chemical, physiological and morphological characterization. Trends Neurosci 1995, 18:527-535.
139. Kawaguchi Y. Physiological, morphological, and histochemical characterization of three classes of interneurons in rat neostriatum. J. Neurosci. 1993, 13:4908-4923.
140. Kawaguchi Y., Wilson C.J., Emson P.C. Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin. J. Neurosci. 1990, 10:3421-3438.
141. Kegel K.B., Kim M., Sapp E., Mclntyre C., Castano J.G., Aronin N., DiFiglia M. Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. J. Neurosci. 2000, 20:7268-7278.
142. Kegel K.B., Meloni A.R., Yi Y., Kim Y.J., Doyle E., Cuiffo B.G., Sapp E., Wang Y., Qin Z.H., Chen J.D., Nevins J.B., Aronin N., DiFiglia M. Huntingtin is present in the nucleus, interacts with the transcriptional co-repressor C-terminal binding protein, and represses transcription. J Biol Chem 2002, 277:7466-7476.
143. Kenney C., Powell S., Jankovic J. Autopsy proven Huntington's disease with 29 trinucleotide repeats. Movement Dis 2006, 22:127-130.
144. Kim T.W., Tanzi R.E. Neuronal intranuclear inclusions in polyglutamine diseases: nuclear weapons or nuclear fallout. Neuron 1998, 21:657-659.
145. Kipps C.M., Duggins A.J., McCusker E.A., Calder A.J. Disgust and happiness recognition correlate with anteroventral insula and amygdala volume respectively in preclinical Huntington's disease. J Cog Neurosci 2007, 19:1206-1217.
146. Kish S.J., Shannak K., Hornykiewicz O. Elevated serotonin and reduced dopamine in subregionally divided Huntington's disease striatum. Ann. Neurol. 1987, 22:386-389.
147. Kita H., Kosaka T., Heizmann C.W. Parvalbumin-immunoreactive neurons in the rat neostriatum: a light and electron microscopic study. Brain Res. 1990, 536:1-15.
148. Klöppel S., Stonnington C.M., Barnes J., Chen F., Chu C., Good C.D., Mader I., Mitchell L.A., Patel A.C., Roberts C.C., Fox N.C., Jack C.R., Ashburner J., Frackowiak R.S. Accuracy of dementia diagnosis: a direct comparison between radiologists and a computerized method. Brain 2008, 131:2969-2974.
149. Ko J., Ou S., Patterson P.H. New antihuntingtin monoclonal antibodies: Implications for huntingtin conformation and its binding proteins. Brain Res. Bull 2001, 56:319-329.
150. Koeppen A.H. The nucleus pontis centralis caudalis in Huntington's disease. J Neuro Sci 1989, 91:126-141.
151. Kok S.W., Overeem S., Visscher T.L., Lammers G.J., Seidell J.C., Pijl H., Meinders A.E. Hypocretin deficiency in narcoleptic humans is associated with abdominal obesity. Obes Res 2003, 11:1147-1154.
152. Koos T., Tepper J.M. Inhibitory control of neostriatal projection neurons by GABAergic interneurons. Nat. Neurosci 1999, 2:467-472.
153. Kovtun I.V., Therneau T.M., McMurray C.T. Gender of the embryo contributes to CAG instability in transgenic mice containing a Huntington's disease gene. Hum. Mol. Gen. 2000, 9:2767-2775.
154. Kovtun I.V., Welch G., Guthrie H.D., Hafner K.L., McMurray C.T. CAG repeat lengths in X-and Y-bearing sperm indicate that gender bias during transmission of Huntington's disease gene is determined by the embryo. J Biol Chem. 2004, 279:9389-9391.
155. Kovtun I.V., Liu Y., Bjoras M., Klungland A., Wilson S.H., McMurray C.T. OGG1 initiates age-dependent CAG trinucleotide expansion in somatic cells. Nature. 2007, 447:447-452.
156. Kowall N.W., Ferrante R.J., Martin J.B. Pattern of cell loss in Huntington's disease. Trends Neurosci 1987, 10:24-29.
157. Kremer H.P., Roos R.A., Dingjan G., Marani E., Bots G.T. Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease. J. Neuropathol. Exp. Neurol. 1990, 49:371-382.
158. Kremer B., Goldberg P., Andrew S.E., Theilmann J., Telenius H., Zeisler J., Squitieri F., Lin B., Bassett A., Almqvist E., Bird T.D., Hayden M.R. A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. N. Engl. J. Med. 1994, 330:1401-1406.
159. Kubota Y., Mikawa S., Kawaguchi Y. Neostriatal GABAergic interneurons contain NOS, calretinin or parvalbumin. NeuroReport 1993, 5:205-208.
160. Kuemmerle S., Gutekunst C.A., Klein A.M., Li X.J., Li S.H., Beal M.F., Hersch S.M., Ferrante R.J. Huntingtin aggregates may not predict neuronal death in Huntington's disease. Ann. Neurol. 1999, 46:842-849.
161. Kuwert T., Lange H.W., Boecker H., Titz H., Herzog H., Aulich A., Wang B.C., Nayak U., Feinendegen L.E. Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease. J Neurol 1993, 241:31-36.
162. Landwehrmeyer G.B., McNeil S.M., Dure IVL.S., Ge P., Aizawa H., Huang Q., Ambrose C.M., Duyao M.P., Bird E.D., Bonilla E., deYoung M., Avila-Gonzales A.J., Wexler N.S., DiFiglia M., Gusella J.F., MacDonald M.E., Penney J.B., Young A.B., Vonsattel J.P. Huntington's disease gene: regional and cellular expression in brain of normal and affected individuals. Ann. Neurol. 1995, 37:218-230.
163. Lange H., Thörner G., Hopf A., Schröder K.F. Morphometric studies of the neuropathological changes in choreatic diseases. J Neurol Sci 1976, 28:401-425.
164. Leeflang E.P., Tavaré S., Marjoram P., Neal C.O., Srinidhi J., MacFarlane H., MacDonald M.E., Gusella J.F., de Young M., Wexler N.S., Arnheim N. Analysis of germline mutation spectra at the Huntingtons disease locus supports a mitotic mutation mechanism. Hum. Mol. Gen. 1999, 8:173-183.
165. Le Moine C., Bloch B. D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J Comp Neurol 1995, 355:418-426.
166. Li J.L., Hayden M.R., Almqvist E.W., Brinkman R.R., Dürr A., Dodé C., Morrison P.J., Suchowersky O., Ross C.A., Margolis R.L., Rosenblatt A., Gómez-Tortosa E., Cabrero D.M., Novelletto A., Frontali M., Nance M., Trent R.J., McCusker E., Jones R., Paulsen J.S., Harrison M., Zanko A., Abramson R.K., Russ A.L., Knowlton B., Djoussé L., Mysore J.S., Tariot S., Gusella M.F., Wheeler V.C., Atwood L.D., Cupples L.A., Saint-Hilaire M., Cha J.H., Hersch S.M., Koroshetz W.J., Gusella J.F., MacDonald M.E., Myers R.H. A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. Am J Hum. Gen. 2003, 73:682-687.
167. Li J.L., Hayden M.R., Warby S.C., Dürr A., Morrison P.J., Nance M., Ross C.A., Margolis R.L., Rosenblatt A., Squitieri F., Frati L., Gómez-Tortosa E., García C.A., Suchowersky O., Klimek M.L., Trent R.J., McCusker E., Novelletto A., Frontali M., Paulsen J.S., Jones R., Ashizawa T., Lazzarini A., Wheeler V.C., Prakash R., Xu G., Djoussé L., Mysore J.S., Gillis T., Hakky M., Cupples L.A., Saint-Hilaire M.H., Cha J.H., Hersch S.M., Penney J.B., Harrison M.B., Perlman S.L., Zanko A., Abramson R.K., Lechich A.J., Duckett A., Marder K., Conneally P.M., Gusella J.F., MacDonald M.E., Myers R.H. Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD-MAPS study. BMC Med Gen 2006, 7:71.
168. Li S.H., Schilling G., Young W.S., 3rd, Li X.J., Margolis R.L., Stine O.C., Wagster M.V., Abbott M.H., Franz M.L., Ranen N.G., Folstein S.E., Hedreen J.C., Ross C.A. Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron 1993, 11:985-993.
169. Li S.H., Li X.J. Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats. Hum. Mol. Gen. 1998, 7:777-782.
170. Li Z., Karlovich C.A., Fish M.P., Scott M.P., Myers R.M. A putative Drosophila homolog of the Huntington's disease gene. Hum. Mol. Gen. 1999, 8:1807-1815.
171. Lievens J.C., Woodman B., Mahal A., Spasic-Boscovic O., Samuel D., Kerkerian-Le G.L., Bates G.P. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol. Dis. 2001, 8:807-821.
172. Lin B., Nasir J., Kalchman M.A., McDonald H., Zeisler J., Goldberg Y.P., Hayden M.R. Structural analysis of the 5' region of the mouse and human Huntington's disease genes reveals conservation of putative promoter region and di-and trinucleotide polymorphisms. Genomics 1995, 25:707-715.
173. Lin C.H., Tallaksen-Greene S., Chien W.M., Cearley J.A., Jackson W.S., Crouse A.B., Ren S., Li X.J., Albin R.L., Detloff P.J. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Gen. 2001, 10:137-144.
174. Luthi-Carter R., Hanson S.A., Strand A.D., Bergstrom D.A., Chun W., Peters N.L., Woods A.M., Chan Kooperberg E.Y., Krainc C.D., Young A.B., Tapscott S.J., Olson J.M. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Gen. 2002, 11:1911-1926.
175. Maat-Kievit A., Helderman-van den Enden P., Losekoot M., de Knijff P., Belfroid R., Vegter-van der Vlis M., Roos R., Breuning M. Using a roster and haplotyping is useful in risk assessment for persons with intermediate and reduced peetrance alleles in Huntington disease. Am. J. Med. Gen. 2001, 105:737-744.
176. Maat-Schieman M.L., Dorsman J.C., Smoor M.A., Siesling S., Van Duinen S.G., Verschuuren J.J., den Dunnen J.T., Van Ommen G.J., Roos R.A. Distribution of inclusions in neuronal nuclei and dystrophic neurites in Huntington disease brain. J. Neuropathol. Exp. Neurol. 1999, 58:129-137.
177. MacDonald M.E., Barnes G., Srinidhi J., Duyao M.P., Ambrose C.M., Myers R.H., Gray J., Conneally P.M., Young A., Penney J. Gametic but not somatic instability of CAG repeat length in Huntington's disease. J. Med. Gen. 1993, 30:982-986.
178. MacDonald M.E., Vonsattel J.P., Shrinidhi J., Couropmitree N.N., Cupples L.A., Bird E.D., Gusella J.F., Myers R.H. Evidence for the GluR6 gene associated with younger onset age of Huntington's disease. Neurology. 1999, 53:1330-1332.
179. MacDonald V., Halliday G. Pyramidal cell loss in motor cortices in Huntington's disease. Neurobiol. Dis. 2002, 10:378-386.
180. Mailleux P., Vanderhaeghen J.J. Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons. Neurosci. Lett. 1992, 148:173-176.
181. Manley K., Shirley T.L., Flaherty L., Messer A. Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice. Nat. Gen. 1999, 23:471-473.
182. Mann D.M., Oliver R., Snowden J.S. The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy. Acta Neuropathol. 1993, 85:553-559.
183. Margolis R.L., Ross C.A. Diagnosis of Huntington disease. Clin. Chem. 2003, 49:1726-1732.
184. Martindale D., Hackam A., Wieczorek A., Ellerby L., Wellington C., McCutcheon K., Singaraja R., Kazemi-Esfarjani P., Devon R., Kim S.U., Bredesen D.E., Tufaro F., Hayden M.R. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nature Gen. 1998, 18:150-154.
185. Massouh M., Wallman M.J., Pourcher E., Parent A. The fate of the large striatal interneurons expressing calretinin in Huntington's disease. Neurosci. Res. 2008, 62:216-224.
186. Matsuyama N., Hadano S., Onoe K., Osuga H., Showguchi-Miyata J., Gondo Y., Ikeda J.E. Identification and characterization of the miniature pig Huntington's disease gene homolog: evidence for conservation and polymorphism in the CAG triplet repeat. Genomics 2000, 69:72-85.
187. McGowan D.P., van Roon-Mom W., Holloway H., Bates G.P., Mangiarini L., Cooper G.J., Faull R.L., Snell R.G. Amyloid-like inclusions in Huntington's disease. Neuroscience 2000, 100::677-680.
188. McNeil S.M., Novelletto A., Srinidhi J., Barnes G., Kornbluth I., Altherr M.R., Wasmuth J.J., Gusella J.F., MacDonald M.E., Myers R.H. Reduced penetrance of the Huntington's disease mutation. Hum. Mol. Gen. 1997, 6:775-779.
189. Medina L., Figueredo-Cardenas G., Reiner A. Differential abundance of superoxide dismutase in interneurons versus projection neurons in patch versus matrix neurons in monkey striatum. Brain Res. 1996, 708:59-70.
190. Metzger S., Rong J., Nguyen H.P., Cape A., Tomiuk J., Soehn A.S., Propping P., Freudenberg-Hua Y., Freudenberg J., Tong L., Li S.H., Li X.J., Riess O. Huntingtin-associated protein-1 is a modifier of the age-at-onset of Huntington's disease. Hum. Mol. Gen. 2008, 17:1137-1146.
191. Metzger S., Saukko M., Van Che H., Tong L., Puder Y., Riess O., Nguyen H.P. Age at onset in Huntington's disease is modified by the autophagy pathway: implication of the V471A polymophism in Atg7. Hum. Gen. 2010, 128:453-459.
192. Möller T. Neuroinflammation in Huntington's disease. J. Neural Transm. 2010, 117:1001-1008.
193. Mormone E., Matarrese P., Tinari A., Cannella M., Maglione V., Farrace M.G., Piacentini M., Frati L., Malorni W., Squitieri F. Genotype-dependent priming of self-and xeno-canibalism in heterozygous lymphoblasts from patients with Huntington's disease. J. Neurochem. 2006, 98:1090-1099.
194. Morton A.J., Faull R.L., Edwardson J.M. Abnormalities in the synaptic vesicle fusion machinery in Huntington's disease. Brain Res. Bull 2001, 56:111-117.
195. Mühlau M., Weindl A., Wohlschläger A.M., Gaser C., Städtler M., Valet M., Zimmer C., Kassubek J., Peinemann A. Voxel-based morphometry indicates relative preservation of the limbic prefrontal cortex in early Huntington disease. J. Neural Transm. 2007, 114:367-372.
196. Myers R.H. Huntington's disease genetics. NeuroRx. 2004, 1:255-262.
197. Myers R.H., Leavitt J., Farrer L.A., Jagadeesh J., McFarlane H., Mastromauro C.A., Mark R.J., Gusella J.F. Homozygote for Huntington disease. Am. J. Hum. Gen. 1989, 45:615-618.
198. Nance M.A., Mathias-Hagen V., Breningstall G., Wick M.J., McGlennen R.C. Analysis of a very large trinucleotide repeat in a patient with juvenile Huntington's disease. Neurology 1999, 52:392-394.
199. Nance M.A., Myers R.H. Juvenile onset Huntington's disease - clinical and research perspectives. Ment. Retard. Dev. Disabil. Res. Rev. 2001, 7:153-157.
200. Narain Y., Wyttenbach A., Rankin J., Furlong R.A., Rubinsztein D.C. A molecular investigation of true dominance in Huntington's disease. J. Med. Gen. 1999, 36:739-746.
201. Norris P.J., Waldvogel H.J., Faull R.L., Love D.R., Emson P.C. Decreased neuronal nitric oxide synthase messenger RNA and somatostatin messenger RNA in the striatum of Huntington's disease. Neuroscience 1996, 72:1037-1047.
202. Nucifora F.C., Sasaki M., Peters M.F., Huang H., Cooper J.K., Yamada M., Takahashi H., Tsuji S., Troncoso J., Dawson V.L., Dawson T.M., Ross C.A. Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity. Science 2001, 291:2423-2428.
203. Ona V.O., Li M., Vonsattel J.P., Andrews L.J., Khan S.Q., Chung W.M., Frey A.S., Menon A.S., Li X.J., Stieg P.E., Yuan J., Penney J.B., Young A.B., Cha J.H., Friedlander R.M. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 1999, 399:263-267.
204. Oyanagi K., Takeda S., Takahashi H., Ohama E., Ikuta F. A quantitative investigation of the substantia nigra in Huntington's disease. Ann. Neurol. 1989, 26:13-19.
205. Parent A., Charara A., Pinault D. Single striatofugal axons arborizing in both pallidal segments and in the substantia nigra in primates. Brain Res. 1995, 698:280-284.
206. Parent A., Smith Y., Filion M., Dumas J. Distinct afferents to the internal and external pallidal segments in the squirrel monkey. Neurosci. Lett. 1989, 96:140-144.
207. Passani L.A., Vonsattel J.P., Coyle J.T. Distribution of N-acetylaspartylglutamate immunoreactivity in human brain and its alteration in neurodegenerative disease. Brain Res. 1997, 772:9-22.
208. Paulsen J.S., Magnotta V.A., Mikos A.E., Paulson H.L., Penziner E., Andreasen N.C., Nopoulos P.C. Brain structure in preclinical Huntington's disease. Biol. Psychiatry. 2006, 59:57-63.
209. Pavese N., Gerhard A., Tai Y.F., Ho A.K., Turkheimer F., Barker R.A., Brooks D.J., Piccini P. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 2006, 66:1638-1643.
210. Petersén Å., Larsen K.E., Behr G.G., Romero N., Przedborski S., Brundin P., Sulzer D. Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration. Hum. Mol. Gen. 2001, 10:1243-1254.
211. Petersén Å., Gil J., Maat-Schieman M.L., Bjorkqvist M., Tanila H., Araujo I.M., Smith R., Popovic N., Wierup N., Norlen P., Li J.Y., Roos R.A., Sundler F., Mulder H., Brundin P. Orexin loss in Huntington's disease. Hum. Mol. Gen. 2005, 14:39-47.
212. Preisinger E., Jordan B.M., Kazantsev A., Housman D. Evidence for a recruitment and sequestration mechanism in Huntinton's disease. Phil. Tran. Royal Soc. Lond. 1999, 354:1029-1034.
213. Qin Z.H., Wang Y., Sapp E., Cuiffo B., Wanker E., Hayden M.R., Kegel K.B., Aronin N., DiFiglia M. Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J. Neurosci. 2004, 24:269-281.
214. Read A.P. Huntington's disease. Nat. Gen. 1993, 4:329-330.
215. Reading S.A., Yassa M.A., Bakker A., Dziorny A.C., Gourley L.M., Yallapragada V., Rosenblatt A., Margolis R.L., Aylward E.H., Brandt J., Mori S., van Zijl P., Bassett S.S., Ross C.A. Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. Psychiat. Res: Neuroimaging 2005, 140:55-62.
216. Rebec G.V., Conroy S.K., Barton S.J. Hyperactive striatal neurons in symptomatic Huntington R6/2 mice: variations with behavioral state and repeated ascorbate treatment. Neuroscience 2006, 137:327-336.
217. Reiner A., Albin R.L., Anderson K.D., D'Amato C.J., Penney J.B., Young A.B. Differential loss of striatal projection neurons in Huntington's disease. Proc. Natl. Acad. Sci. USA 1988, 85:5733-5737.
218. Reiner A., Anderson K.D. The patterns of neurotransmitter and neuropeptide co-occurrence among striatal projection neurons: conclusions based on recent findings. Brain Res. Rev 1990, 15:251-265.
219. Reiner A., Medina L., Haber S.N. The distribution of dynorphinergic terminals in striatal target regions in comparison to the distribution of substance P-containing and enkephalinergic terminals in monkeys and humans. Neuroscience 1999, 88:775-793.
220. Reiner A., Dragatsis I., Zeitlin S.O., Goldowitz D. Wild-type huntingtin plays a role in brain development and neuronal survival. Mol. Neurobiol. 2003, 28:259-275.
221. Reynolds G.P., Garrett N.J. Striatal dopamine and homovanillic acid in Huntington's Disease. J. Neural Transmission 1986, 65:151-155.
222. Reynolds G.P., Pearson S.J. Brain GABA levels in asymptomatic Huntington's disease. N. Engl. J. Med. 1990, 323:682.
223. Ribaï P., Nguyen K., Hahn-Barma V., Gourfinkel-An I., Vidailhet M., Legout A., Dodé C., Brice A., Dürr A. Psychiatric and cognitive difficulties as indicators of juvenile Huntington disease onset in 29 patients. Arch. Neurol. 2007, 64:813-819.
224. Richfield E.K., Herkenham M. Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann. Neurol. 1994, 36:577-584.
225. Richfield E.K., Maguire-Zeiss K.A., Cox C., Gilmore J., Voorn P. Reduced expression of preproenkephalin in striatal neurons from Huntington's disease patients. Ann. Neurol. 1995 a, 37:335-343.
226. Richfield E.K., Maguire-Zeiss K.A., Vonkeman H.E., Voorn P. Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients. Ann. Neurol. 1995 b, 38:852-861.
227. Richfield E.K., O'Brien C.F., Eskin T., Shoulson I. Heterogeneous dopamine receptor changes in early and late Huntington's disease. Neurosci. Lett. 1991, 132:121-126.
228. Roos R.A., Pruyt J.F., de Vries J., Bots G.T. Neuronal distribution in the putamen in Huntington's disease. J. Neurol. Neurosurg. Psychiat. 1985, 48:422-425.
229. Roos R.A.C. Neuropathology of Huntington's chorea. Hand Book of Clinical Neurology 1986, 49:315-326. Elsevier, New York.
230. Rosas H.D., Hevelone N.D., Zaleta A.K., Greve D.N., Salat D.H., Fischl B. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 2005, 65:745-747.
231. Rosas H.D., Koroshetz W.J., Chen Y.I., Skeuse C., Vangel M., Cudkowicz M.E., Caplan K., Marek K., Seidman L.J., Makris N., Jenkins B.G., Goldstein J.M. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2003, 60:1615-1620.
232. Ross C.A., Margolis R.L., Rosenblatt A., Ranen N.G., Becher M.W., Aylward E. Huntington disease and the related disorder, dentatorubral-pallidoluysian atrophy (DRPLA). Medicine (Baltimore) 1997, 76:305-338.
233. Ross C.A. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 2002, 35:819-822.
234. Rubinsztein D.C., Leggo J., Coles R., Almqvist E., Biancalana V., Cassiman J.J., Chotai K., Connarty M., Crauford D., Curtis A., Curtis D., Davidson M.J., Differ A.M., Dode C., Dodge A., Frontali M., Ranen N.G., Stine O.C., Sherr M., Abbott M.H., Franz M.L., Graham C.A., Harper P.S., Hedreen J.C., Hayden M.R., et al. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am. J. Hum. Gen. 1996, 59:16-22.
235. Rubinsztein D.C., Leggo J., Chiano M., Dodge A., Norbury G., Rosser E., Craufurd D. Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset in Huntington disease. Proc. Natl. Acad. Sci. USA 1997, 94:3872-3876.
236. Sanchez I., Xu C.J., Juo P., Kakizaka A., Bienis J., Yuan J. Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 1999, 22:623-633.
237. Sapp E., Kegel K.B., Aronin N., Hashikawa T., Uchiyama Y., Tohyama K., Bhide P.G., Vonsattel J.P., DiFiglia M. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropath. Exp. Neurol. 2001, 60:161-172.
238. Sapp E., Penney J., Young A., Aronin N., Vonsattel J.P., DiFiglia M. Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington's disease. J. Neuropathol. Exp. Neurol. 1999, 58:165-173.
239. Sapp E., Ge P., Aizawa H., Bird E., Penny J., Young A.B., Vonsattel J.P., DiFiglia M. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grad Huntington's disease using high resolution image analysis. Neuroscience 1995, 64:397-404.
240. Sapp E., Schwarz C., Chase K., Bhide P.G., Young A.B., Penney J., Vonsattel J.P., Aronin N., DiFiglia M. Huntingtin localization in brains of normal and Huntington's disease patients. Ann. Neurol. 1997, 42:604-612.
241. Saudou F., Finkbeiner S., Devys D., Greenberg M.E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998, 95:55-66.
242. Schiffmann S.N., Jacobs O., Vanderhaeghen J.J. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J. Neurochem. 1991, 57:1062-1067.
243. Schilling G., Sharp A.H., Loev S.J., Wagster M.V., Li S.H., Stine O.C., Ross C.A. Expression of the Huntington's disease (IT15) protein product in HD patients. Hum. Mol. Gen. 1995, 4:1365-1371.
244. Seizinger B.R., Liebisch D.C., Kish S.J., Arendt R.M., Hornykiewicz O., Herz A. Opioid peptides in Huntington's disease: alterations in prodynorphin and proenkephalin system. Brain Res. 1986, 378:405-408.
245. Selemon L.D., Rajkowska G., Goldman-Rakic P.S. Evidence for progression in frontal cortical pathology in late-stage Huntington's disease. J. Comp. Neurol. 2004, 468:190-204.
246. Semaka A., Collins J.A., Hayden M.R. Unstable familial transmissions of Huntington disease alleles with 27-35 CAG repeats (intermediate alleles). Am. J. Med. Gen. B Neuropsychiatr. Gen. 2010, 153B:314-320.
247. Seto-Ohshima A., Emson P.C., Lawson E., Mountjoy C.Q., Carrasco L.H. Loss of matrix calcium binding protein containing neurons in Huntington's disease. Lancet 1988, 1:1252-1255.
248. Sharp A.H., Loev S.J., Schiling G., Li S.H., Li X.J., Bao J., Wagster M.V., Kotzuk J.A., Steiner J.P., Lo A., Hedreen J., Sisodia S., Snyder S.H., Dawson T.M., Ryugo D.D.K., Ross C.A. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron 1995, 14:1065-1074.
249. Sharp A.H., Ross C.A. Neurobiology of Huntington's disease. Neurobiol. Dis. 1996, 3:3-15.
250. Shieh P.B., Hu S.C., Bobb K., Timmusk T., Ghosh A. Identification of a signaling pathway involved in calcium regulation of BDNF expression. Neuron 1998, 20:727-740.
251. Sieradzan K.A., Mechan A.O., Jones L., Wanker E.E., Nukina N., Mann D.M. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp. Neurol. 1999, 156:92-99.
252. Silvestroni A., Faull R.L., Strand A.D., Möller T. Distinct neuroinflammatory profile in post-mortem human Huntington's disease. Neuroreport 2009, 20:1098-1103.
253. Sisodia S.S. Nuclear inclusion in glutamine repeat disorders: are they pernicious, coincidental or beneficial?. Cell 1998, 95:1-4.
254. Smith R., Chung H., Rundquist S., Maat-Schieman M.L., Colgan L., Englund E., Liu Y.J., Roos R.A., Faull R.L., Brundin P., Li J.Y. Cholinergic neuronal defect without cell loss in Huntington's disease. Hum. Mol. Gen. 2006, 15:3119-3131.
255. Smith R., Klein P., Koc-Schmitz Y., Waldvogel H.J., Faull R.L., Brundin P., Plomann M., Li J.Y. Loss of SNAP-25 and rabphilin 3a in sensory-motor cortex in Huntington's disease. J. Neurochem. 2007, 103:115-123.
256. Snell R.G., MacMillan J.C., Cheadle J.P., Fenton I., Lazarou L.P., Davies P., MacDonald M.E., Gusella J.F., Harper P.S., Shaw D.J. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat. Gen. 1993, 4:393-397.
257. Soneson C., Fontes M., Zhou Y., Denisov V., Paulsen J.S., Kirik D., Petersén A. Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis. Neurobiol. Dis. 2010, 40:531-543. Huntington Study Group PREDICT-HD investigators.
258. Sotrel A., Paskevich P.A., Kiely D.K., Bird E.D., Williams R.S., Myers R.H. Morphometric analysis of the prefrontal cortex in Huntington's disease. Neurology 1991, 41:1117-1123.
259. Sotrel A., Williams R.S., Kaufmann W.E., Myers R.H. Evidence for neuronal degeneration and dendritic plasticity in cortical pyramidal neurons of Huntington's disease: a quantitative Golgi study. Neurology 1993, 43:2088-2096.
260. Spokes E.G.S. Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue. Brain 1980, 103:179-210.
261. Spokes E.G.S., Garrett N.J., Rossor M.N., Iversen L.L. Distribution of GABA in post-mortem brain tissue from control, psychotic and Huntington's chorea subjects. J. Neurol. Sci. 1980, 48:303-313.
262. Squitieri F., Gellera C., Cannella M., Mariotti C., Ciskaghi G., Rubinsztein D.C., Almqvist E.W., Turner D., Bachoud-Levi A.C., Simpson S.A., Delatycki M., Maglione V., Hayden M.R., DiDonato S. Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain 2003, 126:946-955.
263. Squitieri F., Frati L., Ciarmiello A., Lastoria S., Quarrell O. Juvenile Huntington's disease: does a dosage-effect pathogenic mechanism differ from the classical adult disease?. Mech. Aging Dev. 2006, 127:208-212.
264. Squitieri F., Cannella M., Simonelli M., Sassone J., Martino T., Venditti E., Ciammola A., Colonnese C., Frati L., Ciarmiello A. Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease. CNS Neurosci. Ther. 2009, 15:1-11.
265. Squitieri F., Falleni A., Cannella M., Orobello S., Fulceri F., Lenzi P., Fornai F. Abnormal morphology of peripheral cell tissues from patients with Huntington disease. J. Neural Transm. 2010, 117:77-83.
266. Storey E., Beal M.F. Neurochemical substrates of rigidity and chorea in Huntington's disease. Brain 1993, 116:1201-1222.
267. Strong T.V., Tagle D.A., Valdes J.M. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nat. Gen. 1993, 5:259-265.
268. Swami M., Hendricks A.E., Gillis T., Massood T., Mysore J., Myers R.H., Wheeler V.C. Somatic expansion of the Huntington's disease CAG repeat in the brain is associated with an earlier age of disease onset. Hum. Mol. Gen. 2009, 18:3039-3047.
269. Tai Y.F., Pavese N., Gerhard A., Tabrizi S.J., Barker R.A., Brooks D.J., Piccini P. Imaging microglial activation in Huntington's disease. Brain Res. Bull 2007, 72:148-151.
270. Tang T.S., Guo C., Wang H., Chen X., Bezprozvanny I. Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse mode. J. Neurosci. 2009, 29:1257-1266.
271. Tao X., Finkbeiner S., Arnold D.B., Shaywitz A., Greenberg M.E. Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 1998, 20:709-726.
272. Telenius H., Kremer B., Goldberg Y.P., Theilmann J., Andrew S.E., Zeisler J., Adam S., Greenberg C., Ives E.J., Clarke L.A., Hayden M.R. Somatic and gonadal mosaicism of the Huntington disease gene CAG repeat in the brain and sperm. Nat. Gen. 1994, 6:409-414.
273. Thomas L.B., Gates D.J., Richfield E.K., O'Brien T.F., Schweitzer J.B., Steindler D.A. DNA end labeling (TUNEL) in Huntington's disease and other neuropathological conditions. Exp. Neurol. 1995, 133:265-272.
274. Thu D.C., Oorschot D.E., Tippett L.J., Nana A.L., Hogg V.M., Synek B.J., Luthi-Carter R., Waldvogel H.J., Faull R.L. Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease. Brain 2010, 133:1094-1110.
275. Timmers H.J., Swaab D.F., van de Nes J.A., Kremer H.P. Somatostatin 1-12 immunoreactivity is decreased in the hypothalamic lateral tuberal nucleus of Huntington's disease patients. Brain Res. 1996, 728:141-148.
276. Tippett L.J., Waldvogel H.J., Thomas S.J., Hogg V.M., van Roon-Mom W., Synek B.J., Graybiel A.M., Faull R.L. Striosomes and mood dysfunction in Huntington's disease. Brain 2007, 130:206-221.
277. van Roon-Mom W.M., Hogg V.M., Tippett L.J., Faull R.L. Aggregate distribution in frontal and motor cortex in Huntington's disease brain. Neuroreport 2006, 17:667-670.
278. van Roon-Mom W.M., Reid S.J., Jones A.L., MacDonald M.E., Faull R.L., Snell R.G. Insoluble TATA-binding protein accumulation in Huntington's disease cortex. Mol. Brain Res. 2002, 109:1-10.
279. Varani K., Abbracchio M.P., Cannella M., Cislaghi G., Giallonardo P., Mariotti C., Cattabriga E., Cattabeni F., Borea P.A., Squitieri F., Cattaneo E. Aberrant A2A receptor function in peripheral blood cells in Huntington's disease. FASEB J. 2003, 17:2148-2150.
280. Veitch N.J., Ennis M., McAbney J.P., Shelbourne P.F., Monckton D.G. Inherited CAG.CTG allele length is a major modifier of somatic length variability in Huntington's disease. DNA Repair 2007, 6:789-796.
281. Velier J., Kim M., Schwarz C., Kim T.W., Sapp E., Chase K., Aronin N., DiFiglia M. Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways. Exp. Neurol. 1998, 152:34-40.
282. Vis J.C., Nicholson L.F., Faull R.L., Evans W.H., Severs N.J., Green C.R. Connexin expression in Huntington's diseased human brain. Cell. Biol. Int. 1998, 11-12:837-847.
283. Vis J.C., Schipper E., de Boer-van Huizen R.T., Verbeek M.M., de Waal R.M., Wesseling P., ten Donkelaar H.J., Kremer B. Expression pattern of apoptosis-related markers in Huntington's disease. Acta Neuropath 2005, 109:321-328.
284. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 1985, 44:559-577.
285. Vonsattel J.P. Huntington disease models and human neuropathology: similarities and differences. Acta Neuropathol. 2008, 115:55-69.
286. Vonsattel J.P., DiFiglia M. Huntington disease. J Neuropathol. Exp. Neurol. 1998, 57:369-384.
287. Wacker J.L., Huang S.Y., Steele A.D., Aron R., Lotz G.P., Nguyen Q., Giorgini F., Roberson E.D., Lindquist S., Masliah E., Muchowski P.J. Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease. J. Neurosci. 2009, 29. 9104-1914.
288. Walker F.O., Young A.B., Penney J.B., Dovorini-Zis K., Shoulson I. Benzodiazepine and GABA receptors in early Huntington's disease. Neurology 1984, 34:1237-1240.
289. Walker F.O. Huntington's disease. Lancet 2007, 369:118-218.
290. Warby S.C., Montpetit A., Hayden A.R., Carroll J.B., Butland S.L., Visscher H., Collins J.A., Semaka A., Hudson T.J., Hayden M.R. CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am. J. Hum. Gen. 2009, 84:351-366.
291. Weeks R.A., Piccini P., Harding A.E., Brooks D.J. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann. Neurol. 1996, 40:49-54.
292. Wexler N.S., Young A.B., Tanzi R.E., Travers H., Starosta-Rubinstein S., Penney J.B., Snodgrass S.R., Shoulson I., Gomez F., Ramos Arroyo M.A., Penchaszadeh G.K., Moreno H., Gibbons K., Faryniarz A., Hobbs W., Anderson M.A., Bonilla E., Conneally P.M., Gusella J.F. Homozygotes for Huntington disease. Nature 1987, 326:194-197.
293. Wexler N.S., Lorimer J., Porter J., Gomez F., Moskowitz C., Shackell E., Marder K., Penchaszadeh G., Roberts S.A., Gayán J., Brocklebank D., Cherny S.S., Cardon L.R., Gray J., Dlouhy S.R., Wiktorski S., Hodes M.E., Conneally P.M., Penney J.B., Gusella J., Cha J.H., Irizarry M., Rosas D., Hersch S., Hollingsworth Z., MacDonald M., Young A.B., Andresen J.M., Housman D.E., De Young M.M., Bonilla E., Stillings T., Negrette A., Snodgrass S.R., Martinez-Jaurrieta M.D., Ramos-Arroyo M.A., Bickham J., Ramos J.S., Marshall F., Shoulson I., Rey G.J., Feigin A., Arnheim N., Acevedo-Cruz A., Acosta L., Alvir J., Fischbeck K., Thompson L.M., Young A., Dure L., O'Brien C.J., Paulsen J., Brickman A., Krch D., Peery S., Hogarth P., Higgins D.S., Landwehrmeyer B. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc. Natl. Acad. Sci. USA 2004, 101:3498-3503. U.S.-Venezuela Collaborative Research Project.
294. Wheeler V.C., White J.K., Gutekunst C.A., Vrbanac V., Weaver M., Li X.J., Li S.H., Yi H., Vonsattel J.P., Gusella J.F., Hersch S., Auerbach W., Joyner A.L., MacDonald M.E. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum. Mol. Gen. 2000, 9:503-513.
295. Wheeler V.C., Persichetti F., McNeil S.M., Mysore J.S., Mysore S.S., MacDonald M.E., Myers R.H., Gusella J.F., Wexler N.S. Factors associated with HD CAG repeat instability in Huntington disease. J. Med. Gen. 2007, 44:695-701. US-Venezuela Collaborative Research Group.
296. Wilkinson F.L., Man N.T., Manilal S.B., Thomas P., Neal J.W., Harper P.S., Jones A.L., Morris G.E. Localization of rabbit huntingtin using a new panel of monoclonal antibodies. Mol. Brain Res. 1999, 69:10-20.
297. Wilson R.S., Como P.G., Garron D.C., Klawans H.L., Barr A., Klawans D. Memory failure in Huntington's disease. J. Clin. Exp. Neuropsychol. 1987, 9:147-154.
298. Wolf R.C., Sambataro F., Vasic N., Schönfeldt-Lecuona C., Ecker D., Landwehrmeyer B. Aberrant connectivity of lateral prefrontal networks in presymptomatic Huntington's disease. Exp. Neurol. 2008, 213:137-144.
299. Wood J.D., McLaughlin J.C., Harper P.S., Lowenstein P.R., Jones A.L. Partial characterization of murine huntingtin and apparent variations in the subcellular localization of huntingtin in human, mouse and rat brain. Hum. Mol. Gen. 1996, 5:481-487.
300. Wu Y., Richard S., Parent A. The organization of the striatal output system: a single-cell juxtacellular labeling study in the rat. Neurosci. Res. 2000, 38:49-62.
301. Yohrling G.J., Jiang G.C., DeJohn M.M., Miller D.W., Young A.B., Vrana K.E., Cha J.H. Analysis of cellular, transgenic and human models of Huntington's disease reveals tyrosine hydroxylase alterations and substantia nigra neuropathology. Brain Res. Mol. Brain Res. 2003, 119:28-36.
302. Zech M., Roberts G.W., Bogerts B., Crow T.J., Polak J.M. Neuropeptides in the amygdala of controls, schizophrenics and patients suffering from Huntington's chorea: an immunohistochemical study. Acta Neuropathol. 1986, 71:259-266.
303. Zeron M.M., Hansson O., Chen N., Wellington C.L., Leavitt B.R., Brundin P., Hayden M.R., Raymond L.A. Increased sensitivity to N-methyl-d-aspartate receptor-mediated exciitotoxicity in a mouse model of Huntington's disease. Neuron 2002, 33:849-860.
304. Zuccato C., Liber D., Ramos C., Tarditi A., Rigamonti D., Tartari M., Valenza M., Cattaneo E. Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol. Res. 2005, 52:133-139.
305. Zucker B., Kama J.A., Kuhn A., Thu D., Orlando L.R., Dunah A.W., Gokce O., Taylor D.M., Lambeck J., Friedrich B., Lindenberg K.S., Faull R.L., Weiller C., Young A.B., Luthi-Carter R. Decreased Lin7b expression in layer 5 pyramidal neurons may contribute to impaired corticostriatal connectivity in huntington disease. J. Neuropathol. Exp. Neurol. 2010, 69:880-895.